Whalerock Point Partners Has Lowered By $494,250 Its Gilead Sciences (GILD) Stake; Kayne Anderson Capital Advisors LP Has Boosted Ares Cap (ARCC) Holding By $644,520

June 22, 2018 - By Nellie Frank

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Whalerock Point Partners Llc decreased Gilead Sciences Inc (GILD) stake by 27.31% reported in 2018Q1 SEC filing. Whalerock Point Partners Llc sold 6,590 shares as Gilead Sciences Inc (GILD)’s stock declined 17.62%. The Whalerock Point Partners Llc holds 17,544 shares with $1.32 million value, down from 24,134 last quarter. Gilead Sciences Inc now has $93.00B valuation. The stock increased 0.08% or $0.06 during the last trading session, reaching $71.52. About 5.39 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since June 22, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: 14/05/2018 – Gilead’s Epclusa Falls After 3-Wk Rise, Mavyret Advances: Hep-C; 18/05/2018 – FDA- PRELIM RESULTS FROM ONGOING STUDY FOUND WOMEN GETTING DOLUTEGRAVIR AT TIME OF BECOMING PREGNANT/EARLY IN FIRST TRIMESTER APPEAR AT HIGHER RISK FOR DEFECTS; 07/05/2018 – Gilead’s Odefsey Falls For 3rd Wk, Triumeq Declines: HIV; 23/05/2018 – Startup Headed by Gilead Ex-Partner Lures Away Its Top Scientist; 13/04/2018 – Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH; 30/05/2018 – GILEAD: EQUATOR ACHIEVES PRIMARY ENDPOINT; 12/03/2018 – Gilead Sciences Says Norbert Bischofberger to Step Dn as Chief Scientific Officer Effective at End Apri; 01/05/2018 – GILEAD CHIEF SCIENTIFIC OFFICER JOHN MCHUTCHISON SPEAKS ON CALL; 26/04/2018 – CAFC: GILEAD SCIENCES, INC. v. MERCK & CO., INC. [ERRATA] – Appeal #16-2302 – 2018-04-26; 27/04/2018 – Gilead’s Biktarvy Gets Positive Recommendation in Europe

Kayne Anderson Capital Advisors Lp increased Ares Cap Corp (ARCC) stake by 72.46% reported in 2018Q1 SEC filing. Kayne Anderson Capital Advisors Lp acquired 42,968 shares as Ares Cap Corp (ARCC)’s stock rose 4.82%. The Kayne Anderson Capital Advisors Lp holds 102,268 shares with $1.62M value, up from 59,300 last quarter. Ares Cap Corp now has $7.15B valuation. It closed at $16.76 lastly. It is down 0.18% since June 22, 2017 and is downtrending. It has underperformed by 12.75% the S&P500. Some Historical ARCC News: 03/04/2018 – Ares Capital Corporation Schedules Earnings Release for the First Quarter Ended March 31, 2018; 28/05/2018 – ARES ASIA LTD 0645.HK – EXPECTED NET LOSS MAINLY DUE TO DECREASE IN REVENUE DURING YEAR BY ABOUT 20% TO 25%; 06/03/2018 – Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley; 04/04/2018 – ARES CAPITAL IN AMENDED CREDIT FACILITY,BOOSTS BY $25M TO $2.1B; 21/03/2018 – Apollo to Ares Among Surprise Winners in Congress’ Spending Bill; 19/03/2018 – Exclusive – Ares, Hancock find buyer for New England plant; 02/04/2018 – ARCC TO DISCUSS PLAN FOR IMPLEMENTATION OF BDC LAW WITH BOARD; 30/03/2018 – S&PGR Asgns Prelim Rtgs To 2 Classes From Ares XXXIIR CLO Ltd; 26/04/2018 – Moody’s Assigns Ratings To Nine Classes Of Notes Issued By Ares Xxxiir Clo Ltd; 02/05/2018 – ARES CAPITAL 1Q TOTAL ASSETS $12.69B

Kayne Anderson Capital Advisors Lp decreased Eqt Midstream Partners Lp (NYSE:EQM) stake by 377,500 shares to 2.29M valued at $135.41M in 2018Q1. It also reduced Hoegh Lng Partners Lp (NYSE:HMLP) stake by 231,660 shares and now owns 1.55M shares. Gaslog Partners Lp (NYSE:GLOP) was reduced too.

Investors sentiment increased to 1.14 in 2018 Q1. Its up 0.22, from 0.92 in 2017Q4. It improved, as 32 investors sold ARCC shares while 107 reduced holdings. 48 funds opened positions while 110 raised stakes. 161.27 million shares or 3.08% more from 156.46 million shares in 2017Q4 were reported. D E Shaw & holds 0.03% in Ares Capital Corporation (NASDAQ:ARCC) or 1.22M shares. Private Trust Na holds 30,586 shares or 0.11% of its portfolio. Verition Fund Mgmt Ltd Llc holds 0.06% of its portfolio in Ares Capital Corporation (NASDAQ:ARCC) for 53,656 shares. Financial Counselors stated it has 10,959 shares. Tower Rech Ltd Liability (Trc) owns 0% invested in Ares Capital Corporation (NASDAQ:ARCC) for 1,074 shares. Inv Ltd holds 37,766 shares or 0.04% of its portfolio. New South Cap Mngmt holds 0.35% or 890,359 shares in its portfolio. 113,849 were reported by Hbk Investments L P. Cibc Asset reported 16,193 shares. Pinnacle Fin Prtn Incorporated accumulated 12,121 shares or 0.02% of the stock. Covington Mgmt owns 600 shares for 0% of their portfolio. Gsa Cap Partners Ltd Liability Partnership holds 0.18% of its portfolio in Ares Capital Corporation (NASDAQ:ARCC) for 213,225 shares. Kayne Anderson Capital Advsr Lp has invested 0.02% in Ares Capital Corporation (NASDAQ:ARCC). Stratos Wealth Prtn Ltd, Ohio-based fund reported 127,779 shares. Reliance Trust Co Of Delaware has invested 0.05% in Ares Capital Corporation (NASDAQ:ARCC).

More news for Ares Capital Corporation (NASDAQ:ARCC) were recently published by: Seekingalpha.com, which released: “Upcoming Book Value Declines For This Higher Yielding BDC?” on June 20, 2018. Seekingalpha.com‘s article titled: “TCG BDC Inc.: 9% Dividend Yield With Upside For Rising Interest Rates” and published on June 01, 2018 is yet another important article.

Since January 23, 2018, it had 7 insider buys, and 0 insider sales for $453,564 activity. The insider BARTLETT STEVE bought $3,318. Arougheti Michael J had bought 25,000 shares worth $390,000 on Thursday, March 15. ROLL PENELOPE F also bought $47,430 worth of Ares Capital Corporation (NASDAQ:ARCC) on Thursday, February 15.

Among 18 analysts covering Ares Capital (NASDAQ:ARCC), 13 have Buy rating, 0 Sell and 5 Hold. Therefore 72% are positive. Ares Capital has $19.5 highest and $15.0 lowest target. $17.53’s average target is 4.59% above currents $16.76 stock price. Ares Capital had 28 analyst reports since August 21, 2015 according to SRatingsIntel. BMO Capital Markets maintained it with “Hold” rating and $15.0 target in Tuesday, November 14 report. The stock has “Overweight” rating by JP Morgan on Wednesday, April 11. On Friday, August 21 the stock rating was maintained by Citigroup with “Buy”. The stock of Ares Capital Corporation (NASDAQ:ARCC) has “Buy” rating given on Wednesday, June 14 by Keefe Bruyette & Woods. RBC Capital Markets maintained Ares Capital Corporation (NASDAQ:ARCC) on Friday, November 3 with “Hold” rating. Jefferies maintained Ares Capital Corporation (NASDAQ:ARCC) on Tuesday, August 15 with “Buy” rating. Keefe Bruyette & Woods maintained the shares of ARCC in report on Sunday, July 23 with “Buy” rating. The rating was upgraded by Macquarie Research on Thursday, October 1 to “Outperform”. The stock of Ares Capital Corporation (NASDAQ:ARCC) has “Buy” rating given on Wednesday, September 30 by DA Davidson. The stock of Ares Capital Corporation (NASDAQ:ARCC) has “Outperform” rating given on Friday, August 28 by Raymond James.

Since January 2, 2018, it had 0 insider purchases, and 23 selling transactions for $48.21 million activity. Cogan John Francis sold 5,836 shares worth $379,885. On Tuesday, January 2 the insider MARTIN JOHN C sold $3.68 million. $1.11M worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Alton Gregg H. $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Washington Robin L on Wednesday, February 21. On Tuesday, January 16 Meyers James R sold $8.02 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 100,000 shares. Another trade for 60,000 shares valued at $4.68 million was made by WILSON GAYLE E on Friday, February 9.

Among 31 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $96.61’s average target is 35.08% above currents $71.52 stock price. Gilead Sciences had 132 analyst reports since July 29, 2015 according to SRatingsIntel. Argus Research downgraded the shares of GILD in report on Monday, November 13 to “Hold” rating. The stock has “Buy” rating by Jefferies on Friday, January 26. Argus Research upgraded the stock to “Buy” rating in Thursday, August 31 report. The rating was maintained by Maxim Group on Wednesday, October 28 with “Buy”. Cowen & Co maintained it with “Buy” rating and $90.0 target in Wednesday, October 18 report. The firm earned “Buy” rating on Sunday, October 29 by Mizuho. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Neutral” rating by Credit Suisse on Wednesday, December 20. The firm has “Overweight” rating by Piper Jaffray given on Thursday, November 5. Credit Suisse maintained the stock with “Outperform” rating in Wednesday, March 23 report. The stock has “Hold” rating by BMO Capital Markets on Thursday, July 27.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Does Gilead Have An HBV Blockbuster Drug In The Works?” on June 19, 2018, also Seekingalpha.com with their article: “Gilead Oncology CAR T-Cell Therapies Outlook Compelling” published on June 18, 2018, Seekingalpha.com published: “Gilead: Growth Pick For Your Portfolio” on June 15, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 39th Annual Global Healthcare Conference (Transcript)” published on June 13, 2018 as well as Seekingalpha.com‘s news article titled: “Gilead: Novartis’s Kymriah Is Coming To America” with publication date: May 24, 2018.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.42 earnings per share, down 43.43% or $1.09 from last year’s $2.51 per share. GILD’s profit will be $1.85 billion for 12.59 P/E if the $1.42 EPS becomes a reality. After $1.37 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 3.65% EPS growth.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts